STRATA Skin Sciences, Inc.
STRATA Skin Sciences, Inc. is a U.S.-based medical technology company focused on dermatology devices and treatment systems. Its portfolio includes excimer laser and lamp platforms used by dermatologists to treat psoriasis, vitiligo, acne, and other skin conditions, with sales and procedures centered in the United States and select international markets.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueTreatment revenue from XTRAC procedures and TheraClear device placements recognized over usage.
Sales of excimer lasers, lamp systems, accessories, and related equipment to practices.
Customers
The company sells primarily to dermatology practices and physicians that treat chronic and recurring skin conditions. Its recurring procedures model also serves offices that place STRATA devices and then generate treatment revenue as patients use the systems. Demand is tied to clinical adoption, reimbursement coverage, and the ability of practices to attract patients needing psoriasis, vitiligo, or acne therapy.
Buy XTRAC, Pharos, and VTRAC systems to treat psoriasis, vitiligo, and other skin diseases in-office.
Place STRATA devices and generate treatment revenue as patients return for repeated sessions.
Use TheraClear X for acne-related skin conditions and related patient care workflows.
Purchase equipment and procedures outside the U.S. where the company has international exposure.
Strategy
STRATA’s strategy centers on expanding installed base usage, placing devices in dermatology offices, and converting that footprint into recurring treatment revenue. It also emphasizes product development and commercialization across dermatology indications, while managing the economics of device refurbishment and redeployment to support utilization.
Recurring treatments create repeat revenue tied to installed devices and patient flow.
A larger installed base supports future procedure volume and customer retention.
Refurbishing and redeploying units can lower capital needs versus building new systems.
Geography
Q3/2025STRATA is headquartered in the United States and its reported recurring procedures activity is concentrated there. The company also notes international customer activity, which can affect collections timing and exposure to trade policy, tariffs, and cross-border supply chain costs. Geography matters because the business depends on U.S. reimbursement dynamics while importing components and serving some customers abroad.
Share of the revenue the company reports by geography.
Risks
The business is exposed to reimbursement, adoption, and utilization risk because a meaningful share of revenue depends on repeated dermatology procedures. It also faces tariff, import, and supply-chain risk because products and components may be sourced across borders, while accounting estimates such as revenue deferrals, goodwill, and sales tax liabilities can materially affect reported results.
Imported products or components may become more expensive and less competitive.
Recurring procedure revenue depends on insurance coverage and patient treatment volume.
Exposure: XTRAC and related dermatology procedures
Device and reporting-unit values depend on future cash flow assumptions.
Exposure: Dermatology recurring procedures reporting unit
The company noted longer payment cycles from international customers.
Exposure: Accounts receivable and cash conversion
Accounting
Judgemental itemsRevenue is deferred and recognized as treatments are used, affecting quarterly timing.
Impact: Can shift revenue between periods
Placed devices generate future treatment revenue that is not recognized immediately.
Impact: Affects reported revenue and contract liabilities
The dermatology recurring procedures reporting unit depends on valuation assumptions.
Impact: Can create non-cash charges if expected cash flows weaken
Management disclosed a methodology error that affected accrued expenses and expense recognition.
Impact: Can alter liabilities, operating expense, and goodwill carrying value
Similar listed companies
Publicly listed companies with a comparable business focus.
Strata Critical Medical, Inc.
SRTA · Services-Health Services
Sensus Healthcare, Inc.
SRTS · Surgical & Medical Instruments & Apparatus
Dermata Therapeutics, Inc.
DRMA · Pharmaceutical Preparations
STAAR Surgical Company
STAA · Ophthalmic Goods
STAAR Surgical designs, manufactures, and sells implantable lenses for the eye and the accessory delivery systems used to place them.
Turn Therapeutics Inc.
TTRX · Pharmaceutical Preparations
Caring Brands, Inc.
CABR · Perfumes, Cosmetics & Other Toilet Preparations
Last updated: 24/09/2026